
Reset all filters
01 5Atripla
02 12Biktarvy
03 1Complera
04 1Complera /Eviplera
05 8Complera/Eviplera
06 14Descovy
07 20Genvoya
08 14Odefsey
09 5Prezista/Prezcobix/Rezolsta/Symtuza
10 7Revenue share - Symtuza
11 15Stribild
12 9Symtuza
13 9Truvada
Main Therapeutic Indication : Infectious Diseases
Currency : USD
2020 Revenue in Millions : 269
2019 Revenue in Millions : 406
Growth (%) : -34
Bictegravir, Emtricitabine, Tenofovir Alafenamide
Main Therapeutic Indication : Infectious Diseases
Currency : USD
2020 Revenue in Millions : 1,672
2019 Revenue in Millions : 1,655
Growth (%) : 1
Main Therapeutic Indication : Infectious Diseases
Currency : USD
2020 Revenue in Millions : 7,259
2019 Revenue in Millions : 4,738
Growth (%) : 53
Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Alafenamide
Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Alafenamide
Main Therapeutic Indication : Infectious Diseases
Currency : USD
2020 Revenue in Millions : 3,338
2019 Revenue in Millions : 3,931
Growth (%) : -15
Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Alafenamide
Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Alafenamide
Main Therapeutic Indication : Infectious Diseases
Currency : USD
2020 Revenue in Millions : 2,184
2019 Revenue in Millions : 2,110
Growth (%) : 4
Bictegravir, Emtricitabine, Tenofovir Alafenamide
Main Therapeutic Indication : Infectious Diseases
Currency : USD
2020 Revenue in Millions : 488
2019 Revenue in Millions : 379
Growth (%) : 29
Bictegravir, Emtricitabine, Tenofovir Alafenamide
Main Therapeutic Indication : Infectious Diseases
Currency : USD
2020 Revenue in Millions : 7,259
2019 Revenue in Millions : 4,738
Growth (%) : 53
Bictegravir, Emtricitabine, Tenofovir Alafenamide
Main Therapeutic Indication : Infectious Diseases
Currency : USD
2020 Revenue in Millions : 1,861
2019 Revenue in Millions : 1,500
Growth (%) : 24
Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Alafenamide
Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Alafenamide
Main Therapeutic Indication : Infectious Diseases
Currency : USD
2020 Revenue in Millions : 488
2019 Revenue in Millions : 379
Growth (%) : 29
Bictegravir, Emtricitabine, Tenofovir Alafenamide
Main Therapeutic Indication : Infectious Diseases
Currency : USD
2020 Revenue in Millions : 3,338
2019 Revenue in Millions : 3,931
Growth (%) : -15